| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | LRRK2-IN-1 | CTRPv2 | pan-cancer | AAC | -0.061 | 0.1 |
| mRNA | FK866 | CTRPv2 | pan-cancer | AAC | 0.06 | 0.1 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.051 | 0.1 |
| mRNA | KIN001-102 | GDSC1000 | pan-cancer | AAC | -0.045 | 0.1 |
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | -0.068 | 0.1 |
| mRNA | neopeltolide | CTRPv2 | pan-cancer | AAC | 0.11 | 0.1 |
| mRNA | FR-180204 | GDSC1000 | pan-cancer | AAC | -0.051 | 0.1 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.053 | 0.1 |
| mRNA | TGX221 | CTRPv2 | pan-cancer | AAC | -0.058 | 0.1 |
| mRNA | barasertib | CTRPv2 | pan-cancer | AAC | -0.05 | 0.1 |